Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | — |
The patient did not available for the second dose of Rabavert vaccine on day seven; Case reference number US-BN-2025-001762 is a spontaneous case report initially received from a pharmacist via Bavarian Nordic (reference number: CASE-000586) on 04-Nov-2025 and concerns a male patient of unspecified age. The patient's relevant medical history and concomitant medications were not provided. On 20-Aug-2025, the patients received the first dose of RavAvert vaccine along with its reconstitution parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at unknown dose, route or site of administration for the indication pre-exposure prophylaxis. As reported, the patient did not available for the second dose of Rabavert vaccine on day seven (on 27-Aug-2025) and will not be available to receive it until six months after the first dose (explicitly coded as 'missed dose') . At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert. No further information provided.; Reporter's Comments: This case concerns a male patient of unspecified age, who received first dose of RabAvert vaccine for an indication of pre-exposure prophylaxis. As reported patient did not receive the second dose, even after 6 months, after the first dose, which is considered as product dose omission issue. Product dose omission issue is considered listed per company convention. Patient's medical history and concomitant medication details were not provided. At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert. Product dose omission issue is assessed as not related to suspect vaccine, but to human factor. The case is non-serious.; Sender's Comments: This case concerns a male patient of unspecified age, who received first dose of RabAvert vaccine for an indication of pre-exposure prophylaxis. As reported patient did not receive the second dose, even after 6 months, after the first dose, which is considered as product dose omission issue. Product dose omission issue is considered listed per company convention. Patient's medical history and concomitant medication details were not provided. At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert. Product dose omission issue is assessed as not related to suspect vaccine, but to human factor. The case is non-serious.
Comments: None.